Platinum-based chemotherapy is the backbone of treatment for ovarian cancer, and although the majority of patients initially have a platinum-sensitive disease, through multiple recurrences, they will acquire resistance. Platinum-resistant recurrent ovarian cancer has a poor prognosis and few...
Platinum is a key component of ovarian cancer systemic therapy. However, most patients will eventually face a recurrence, leading to chemotherapy resistance, especially against platinum. For individuals with platinum-resistant ovarian cancer (PROC), treatment options are limited, and their survival prospe...
The median survival of patients with platinum sensitive recurrent ovarian cancer is estimated to be 2 years, but it can range from only a few months to more than a decade. Patients who relapse within 6 months of completing first-line therapy have been classified as being “platinum resistant”...
Introduction: The objective of this review is to summarize results from clinical trials that tested cytotoxic drugs and target strategies for the treatment of platinum resistant (PR) recurrent ovarian cancer (ROC) with particular attention to Phase III and ongoing trials. Areas covered: Since ...
Bevacizumab is an antiangiogenic agent that was approved in 2014 for the treatment of women with platinum-resistant, recurrent ovarian cancer. The approval was based the phase III AURELIA trial that randomized individuals to receive physician’s choice of chemotherapy or chemotherapy with bevacizumab, ...
According to him, patients should be classified into two groups based on these considerations including chemosensitive and chemoresistant.doi:10.3816/COC.2009.n.013J. Tate ThigpenElsevier Inc.Clinical Ovarian Cancer
Treatmentofplatinum—resistantrecurrentovariancancerusinga ‘‘predictivemoleculetargetedroutinechemotherapy’’system ZHAOXiao—dong,WEIFeng—hua,ZHANGYi,HEShu—rongandYANGLi Keywords:ovarianneoplasms;recurrence;chemotherapy;predictivemolecule Background Correctdrugselection.thekeytosuccessfulchemotherapy.isoneofthemostdi...
The objective was to determine the response rate to platinum retreatment of "platinum-resistant" ovarian cancer after intervening nonplatinum therapy. We retrospectively identified 30 patients with platinum-resistant ovarian cancer who received nonplatinum chemotherapy for recurrent epithelial ovarian cancer pr...
To evaluate the efficacy of cytoreductive surgery versus chemotherapy for the treatment of limited regional, platinum-resistant ovarian cancer (PROC). The clinical records of all patients with PROC treated in our center between March 2015 and March 2022
Safety and tolerability of CRX100, an NKT cell therapy combined with tumor-specific oncolytic vaccinia virus among patients with recurrent, platinum-resistant ovarian cancer. Presented at: SGO 2024 Annual Meeting on Women’s Cancer; March 16 – 18, 2024; San Diego; CA. 2. Study of CRX100 ...